On the other side of the debate, critics point to the limitations of this study, which did not
directly compare cetuximab to cisplatin, and the lack of any further phase III studies. They …

Abstract Background: Cetuximab (Erbitux) is the only new medical therapy for locally and
regionally advanced SCCHN to be licensed in industrialized countries in the past 15 years …

PURPOSE: No randomized trials have been conducted to directly compare radiotherapy
(RT) with concomitant cisplatin (CDDP) versus concomitant cetuximab (CTX) as first-line …

Recently, Magrini et al. reported the results of a small randomized phase II study that
included 70 patients with locoregionally advanced head and neck cancer who were …

TO THE EDITOR: Definitive chemoradiotherapy is a standard of care for the treatment of
locally advanced squamous cell carcinoma of the head and neck (LAHNC). A meta-analysis …

Introduction The purpose of this study was to evaluate the clinical efficacy in our daily
practice, outside clinical trials, of cetuximab plus radiotherapy in a majority of treatment …

Combining cetuximab with chemoradiotherapy in locally advanced head and neck squamous
cell carcinoma: is more better? - Abstract - Europe PMC Sign in | Create an account …

Objective. To review the current state of the data on the use of cetuximab in head and neck
squamous cell carcinoma (HNSCC). Data Sources. The National Center for Biotechnology …

The administration of Cetuximab in combination with radiotherapy and chemotherapy has
shown clear survival improvements within the locally advanced and the relapsed/metastatic …

Cetuximab (Erbitux®) is a chimeric monoclonal antibody directed against the human
epidermal growth factor receptor (EGFR). EGFR is overexpressed and/or upregulated in …